Ernexa Therapeutics annual operating margin
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2023
2024
Ernexa Therapeutics's operating margin was −2,693.13% for fiscal 2024.
View full Ernexa Therapeutics company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2024 | 2024-12-31 | −2,693.13% | +28387.76 pp |
| 2023 | 2023-12-31 | −31,080.88% | −30955.92 pp |
| 2020 | 2020-12-31 | −124.97% | −116.07 pp |
| 2019 | 2019-12-31 | −8.90% | −9.77 pp |
| 2018 | 2018-12-31 | 0.87% | +7.46 pp |
| 2017 | 2017-12-31 | −6.59% | +3.62 pp |
| 2016 | 2016-12-31 | −10.21% | +17.91 pp |
| 2015 | 2015-12-31 | −28.12% | −9.91 pp |
| 2014 | 2014-12-31 | −18.21% | −13.49 pp |
| 2013 | 2013-12-31 | −4.71% | −0.30 pp |
| 2012 | 2012-12-31 | −4.41% | +9.31 pp |
| 2011 | 2011-12-31 | −13.72% | −12.44 pp |
| 2010 | 2010-12-31 | −1.28% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q4 2024 | 2024-12-31 | −269,700.00% | −258905.88 pp |
| Q3 2024 | 2024-09-30 | −463.86% | −276.06 pp |
| Q2 2024 | 2024-06-30 | −10,491.49% | −10355.57 pp |
| Q1 2024 | 2024-03-31 | −12,312.77% | −12044.97 pp |
| Q3 2023 | 2023-09-30 | −10,794.12% | −10751.74 pp |
| Q4 2020 | 2020-12-31 | −187.80% | −164.06 pp |
| Q3 2020 | 2020-09-30 | −135.92% | −129.02 pp |
| Q2 2020 | 2020-06-30 | −267.80% | −267.76 pp |
| Q1 2020 | 2020-03-31 | −42.38% | −37.89 pp |
| Q4 2019 | 2019-12-31 | −23.74% | −26.67 pp |
| Q3 2019 | 2019-09-30 | −6.90% | −13.06 pp |
| Q2 2019 | 2019-06-30 | −0.04% | +0.44 pp |
| Q1 2019 | 2019-03-31 | −4.49% | +0.94 pp |
| Q4 2018 | 2018-12-31 | 2.92% | +12.16 pp |
| Q3 2018 | 2018-09-30 | 6.16% | +7.18 pp |
| Q2 2018 | 2018-06-30 | −0.48% | −0.01 pp |
| Q1 2018 | 2018-03-31 | −5.43% | +10.51 pp |
| Q4 2017 | 2017-12-31 | −9.23% | −4.22 pp |
| Q3 2017 | 2017-09-30 | −1.02% | +6.59 pp |
| Q2 2017 | 2017-06-30 | −0.47% | +12.40 pp |
| Q1 2017 | 2017-03-31 | −15.94% | −0.11 pp |
| Q4 2016 | 2016-12-31 | −5.02% | +8.83 pp |
| Q3 2016 | 2016-09-30 | −7.61% | +14.01 pp |
| Q2 2016 | 2016-06-30 | −12.87% | +27.04 pp |
| Q1 2016 | 2016-03-31 | −15.83% | +22.69 pp |
| Q4 2015 | 2015-12-31 | −13.85% | +8.57 pp |
| Q3 2015 | 2015-09-30 | −21.62% | −0.38 pp |
| Q2 2015 | 2015-06-30 | −39.92% | −21.00 pp |
| Q1 2015 | 2015-03-31 | −38.53% | −28.34 pp |
| Q4 2014 | 2014-12-31 | −22.41% | −16.30 pp |
| Q3 2014 | 2014-09-30 | −21.23% | −16.96 pp |
| Q2 2014 | 2014-06-30 | −18.91% | −16.84 pp |
| Q1 2014 | 2014-03-31 | −10.19% | −4.21 pp |
| Q4 2013 | 2013-12-31 | −6.11% | −10.13 pp |
| Q3 2013 | 2013-09-30 | −4.27% | −5.91 pp |
| Q2 2013 | 2013-06-30 | −2.08% | +10687.86 pp |
| Q1 2013 | 2013-03-31 | −5.98% | +10.45 pp |
| Q4 2012 | 2012-12-31 | 4.01% | +11.58 pp |
| Q3 2012 | 2012-09-30 | 1.64% | +15.18 pp |
| Q2 2012 | 2012-06-30 | −10,689.94% | +6657.67 pp |
| Q1 2012 | 2012-03-31 | −16.44% | −7.77 pp |
| Q4 2011 | 2011-12-31 | −7.57% | −9.96 pp |
| Q3 2011 | 2011-09-30 | −13.54% | −6.96 pp |
| Q2 2011 | 2011-06-30 | −17,347.61% | — |
| Q1 2011 | 2011-03-31 | −8.67% | — |
| Q3 2010 | 2010-09-30 | 2.38% | — |
| Q2 2010 | 2010-06-30 | −6.57% | — |
Over the last five reported fiscal years, Ernexa Therapeutics's operating margin decreased from −6.59% to −2,693.13%, a change of −2686.54 percentage points. The latest reported quarter, Q4 2024, shows −269,700.00%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ernexa Therapeutics filings at SEC.gov ↗